Cycloalkane[B]azaindole antagonists of prostaglandin D 2...

Details Cycloalkane[B]azaindole antagonists of prostaglandin D 2... Cycloalkane[B]azaindole antagonists of prostaglandin D 2...

2009-11-05

2011-10-11

Seaman, D M (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S087000

Reexamination Certificate

active

08034826

ABSTRACT:
Described herein are compounds that are antagonists of PGD2receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

REFERENCES:
patent: 5223517 (1993-06-01), Muller et al.
patent: 7144913 (2006-12-01), Wang et al.
patent: 2003/0096813 (2003-05-01), Cao et al.
patent: 2005/0171143 (2005-08-01), Tanimoto et al.
patent: 2005/0272756 (2005-12-01), Leblanc et al.
patent: 2007/0191416 (2007-08-01), Fecher et al.
patent: 2009/0186923 (2009-07-01), Armer et al.
patent: 1170594 (2002-01-01), None
patent: 1505061 (2005-02-01), None
patent: 2465062 (2011-04-01), None
patent: 2004-182657 (2004-07-01), None
patent: WO-2007-070892 (1997-06-01), None
patent: WO-02-085909 (2002-10-01), None
patent: WO-03-062200 (2003-07-01), None
patent: WO-2004-035543 (2004-04-01), None
patent: WO-2004-058164 (2004-07-01), None
patent: WO-2004-096777 (2004-11-01), None
patent: WO-2005-040114 (2005-05-01), None
patent: WO-2005-044260 (2005-05-01), None
patent: WO-2005-095397 (2005-10-01), None
patent: WO-2006-052798 (2006-05-01), None
patent: WO-2006-052798 (2006-05-01), None
patent: WO-2006-070325 (2006-07-01), None
patent: WO-2007-019675 (2007-02-01), None
patent: WO-2007-037187 (2007-04-01), None
patent: WO-2007-107772 (2007-09-01), None
patent: WO-2007-144127 (2007-12-01), None
patent: WO-2008-017989 (2008-02-01), None
patent: WO-2008-019357 (2008-02-01), None
patent: WO-2008-137027 (2008-11-01), None
patent: WO-2008-156780 (2008-12-01), None
patent: WO-2009-004379 (2009-01-01), None
patent: WO-2009-044147 (2009-04-01), None
patent: WO-2009-049021 (2009-04-01), None
patent: WO-2009-063202 (2009-05-01), None
patent: WO-2009-063215 (2009-05-01), None
patent: WO-2009-140642 (2009-11-01), None
patent: WO-2010-008864 (2010-01-01), None
patent: WO-2010-085820 (2010-07-01), None
patent: WO-2010-085820 (2010-07-01), None
patent: WO-2011-014587 (2011-02-01), None
patent: WO-2011-014588 (2011-02-01), None
Kelly et al., Journal of the chemical society [section] C: organic (1970), (2), 303-7.
Blache et al., Compared Reactivity of Heterocyclic Enaminones: Photochemical and Palladium Catalyzed Synthesis of 6,7,8,9-Tetrahydro-5H-pyrido[3,2-b]indol-9-ones, J. Org. Chem. 62(24):8553-8446 (1997).
PCT/US09/063439 Search Report dated Jun. 28, 2010.
PCT/US 09/063438 Search Report dated Jun. 28, 2010.
Arima and Fukuda, “Prostaglandin D2 Receptors DP and CRTH2 in the Pathogenesis of Asthma,” Curr. Mol. Med. 8:365-375 (2008).
Hata and Breyer, “Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation,” Pharmacol. Ther. 103:147-166 (2004).
Kostenis and Ulven, “Emerging roles of DP and CRTH2 in allergic inflammation,” Trends Mol. Med. 12(4):148-158 (2006).
Medina and Liu, “PGD2 Antagonists,” Annual Reports Med. Chem. 41:221-235 (2006).
Pettipher et al., “Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases,” Nature Reviews/Drug Discovery 6:313-325 (2007).
Stearns et al., “Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in murine model of allergic rhinitis,” Bioor. Med. Chem. Letters 19:4647-4651 (2009).
Tirouvanziam et al., “Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways,” PNAS 105(11):4335-4339 (2008).
Ulven and Kostenis, “Targeting the Prostaglandin D2 Receptors DP and CRTH2 for Treatment of Inflammation,” Curr. Topics Med. Chem. 6:1427-1444 (2006).
GB0919199.0 Search Report dated Nov. 18, 2009.
Crosignani et al., “Discovery of a New Class of Potent, Selective, and Orally Bioavailable CRTH2 (DP2) Receptor Antagonists for the Treatment of Allergic Inflammatory Diseases,” J Med Chem 51:2227-2243 (2008).
Evans and Hutchinson, “Seeing the future of bioactive lipid drug targets,” Nature Chem Biol 6:476-479 (2010).
Kim and Luster, “Regulation of Immune Cells by Eicosanoid Receptors,” TheScientificWorldJournal 7:1307-1328 (2007).
Ly and Bacon, “Small-molecule CRTH2 antagonists for the treatment of allergic inflammation: an overview,” Expert Opin Investig Drugs 14(7):769-773 (2005).
Pettipher and Hansel, “Antagonists of the Prostaglandin D2 Receptor CRTH2,” Drug News Perspect 21 (6):317-322 (2008).
Pettipher, R., “The roles of the prostaglandin D2 receptors DP1 and CRTH2 in promoting allergic responses,” Br J Pharmacol 153:S191-S199 (2008).
Prieto et al., “Racemization in Suzuki Couplings: A Quantitative Study Using 4-Hydroxyphenylglycine and Tyrosine Derivatives as Probe Molecules,” J Org Chem 72:1047-1050 (2007).
Sandham et al., “7-Azaindole-3-acetic acid derivatives: Potent and selective CRTH2 receptor antagonists,” Bioorg Med Chem Ltrs 19:4794-4798 (2009).
Sandig et al., “Contrary prostaglandins: the opposing roles of PGD2 and its metabolites in leukocyte function,” J Leukocyte Biol 81:372-382 (2007).
Scott et al., “Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine modelof allergic rhinitis,” Bioorg Med Chem Ltrs accepted Jan. 6, 2011, DOI 10.1016/j.bmcl.2011.01.024.
Stebbins et al., “Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation,” Eur J Pharmacol 638:142-149 (2010).
Stebbins et al., “Pharmacological Blockade of the DP2 Receptor Inhibits Cigarette Smoke-Induced Inflammation, Mucus Cell Metaplasia, and Epithelial Hyperplasia in the Mouse Lung,” J Pharmacol Exp Therapeutics 331 (3):764-775 (2010).
Stebbins et al., “DP2 Receptor Antagonists: Novel Therapeutic Target for COPD,” Mol Cell Pharmacol 2(3):89-96 (2010).
Stock et al., “Sodium [2′-[(cyclopropanecarbonyl-ethyl-amino)-methy1]-4′(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432):A potent, selective prostaglandin D2 receptor antagonist,” Bioorg Med Chem Ltrs 21:1036-1040 (2011).
Takeshita et al., “CRTH2 is a prominent effector in contact hypersensitivity-induced neutrophil inflammation,” Int Immunol 16(7):947-959 (2004).
Torisu et al., “Discovery of new chemical leads for prostaglandin D2 receptor antagonists,” Bioorg Med Chem Ltrs 14:4557-4562 (2004).
Ulven and Kostenis, “Minor Structural Modifications Convert the Dual TP/CRTH2 Antagonist Ramatrobin into a Highly Selective and Potent CRTH2 Antagonist,” J Med Chem 48(4):897-900 (2005).
PCT/US09/44219 International Search Report and Written Opinion mailed Jan. 19, 2010.
PCT/US09/44219 International Preliminary Examination Report mailed Nov. 17, 2010.
PCT/US09/44219 International Preliminary Report on Patentability mailed.
PCT/US09/48327 International Search Report and Written Opinion mailed Jan. 29, 2010.
PCT/US09/48327 International Preliminary Examination Report mailed Jan. 13, 2011.
PCT/US09/48327 International Preliminary Report on Patentability mailed.
Srinivas et al., “Biaryl amino acid templates in place of D-Pro-L-Pro in cyclic beta-hairpin cationic antimicrobial peptidomimetics,” Organic & Biomolecular Chemistry 5(19):3100-3105 (2007).
PCT/US10/43599 Search Report and Written Opinion mailed Apr. 28, 2011.
PCT/US10/43598 Search Report and Written Opinion mailed Apr. 20, 2011.

Affiliated with

Also associated with

Rating

Cycloalkane[B]azaindole antagonists of prostaglandin D 2... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cycloalkane[B]azaindole antagonists of prostaglandin D 2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cycloalkane[B]azaindole antagonists of prostaglandin D 2... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4275652